Cargando…

Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology

Immune checkpoint blockade therapy has revolutionized non-small cell lung cancer treatment. However, not all patients respond to this therapy. Assessing the tumor expression of immune checkpoint molecules, including programmed death-ligand 1 (PD-L1), is the current standard in predicting treatment r...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yen-Yu, Wang, Lei-Chi, Hsieh, Yu-Han, Hung, Yu-Ling, Chen, Yung-An, Lin, Yu-Chieh, Lin, Yen-Yin, Chou, Teh-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925228/
https://www.ncbi.nlm.nih.gov/pubmed/35296339
http://dx.doi.org/10.1186/s12967-022-03335-5
_version_ 1784670024858861568
author Lin, Yen-Yu
Wang, Lei-Chi
Hsieh, Yu-Han
Hung, Yu-Ling
Chen, Yung-An
Lin, Yu-Chieh
Lin, Yen-Yin
Chou, Teh-Ying
author_facet Lin, Yen-Yu
Wang, Lei-Chi
Hsieh, Yu-Han
Hung, Yu-Ling
Chen, Yung-An
Lin, Yu-Chieh
Lin, Yen-Yin
Chou, Teh-Ying
author_sort Lin, Yen-Yu
collection PubMed
description Immune checkpoint blockade therapy has revolutionized non-small cell lung cancer treatment. However, not all patients respond to this therapy. Assessing the tumor expression of immune checkpoint molecules, including programmed death-ligand 1 (PD-L1), is the current standard in predicting treatment response. However, the correlation between PD-L1 expression and anti-PD-1/PD-L1 treatment response is not perfect. This is partly caused by tumor heterogeneity and the common practice of assessing PD-L1 expression based on limited biopsy material. To overcome this problem, we developed a novel method that can make formalin-fixed, paraffin-embedded tissue translucent, allowing three-dimensional (3D) imaging. Our protocol can process tissues up to 150 μm in thickness, allowing anti-PD-L1 staining of the entire tissue and producing high resolution 3D images. Compared to a traditional 4 μm section, our 3D image provides 30 times more coverage of the specimen, assessing PD-L1 expression of approximately 10 times more cells. We further developed a computer-assisted PD-L1 quantitation method to analyze these images, and we found marked variation of PD-L1 expression in 3D. In 5 of 33 needle-biopsy-sized specimens (15.2%), the PD-L1 tumor proportion score (TPS) varied by greater than 10% at different depth levels. In 14 cases (42.4%), the TPS at different depth levels fell into different categories (< 1%, 1–49%, or ≥ 50%), which can potentially influence treatment decisions. Importantly, our technology permits recovery of the processed tissue for subsequent analysis, including histology examination, immunohistochemistry, and mutation analysis. In conclusion, our novel method has the potential to increase the accuracy of tumor PD-L1 expression assessment and enable precise deployment of cancer immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03335-5.
format Online
Article
Text
id pubmed-8925228
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89252282022-03-23 Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology Lin, Yen-Yu Wang, Lei-Chi Hsieh, Yu-Han Hung, Yu-Ling Chen, Yung-An Lin, Yu-Chieh Lin, Yen-Yin Chou, Teh-Ying J Transl Med Research Immune checkpoint blockade therapy has revolutionized non-small cell lung cancer treatment. However, not all patients respond to this therapy. Assessing the tumor expression of immune checkpoint molecules, including programmed death-ligand 1 (PD-L1), is the current standard in predicting treatment response. However, the correlation between PD-L1 expression and anti-PD-1/PD-L1 treatment response is not perfect. This is partly caused by tumor heterogeneity and the common practice of assessing PD-L1 expression based on limited biopsy material. To overcome this problem, we developed a novel method that can make formalin-fixed, paraffin-embedded tissue translucent, allowing three-dimensional (3D) imaging. Our protocol can process tissues up to 150 μm in thickness, allowing anti-PD-L1 staining of the entire tissue and producing high resolution 3D images. Compared to a traditional 4 μm section, our 3D image provides 30 times more coverage of the specimen, assessing PD-L1 expression of approximately 10 times more cells. We further developed a computer-assisted PD-L1 quantitation method to analyze these images, and we found marked variation of PD-L1 expression in 3D. In 5 of 33 needle-biopsy-sized specimens (15.2%), the PD-L1 tumor proportion score (TPS) varied by greater than 10% at different depth levels. In 14 cases (42.4%), the TPS at different depth levels fell into different categories (< 1%, 1–49%, or ≥ 50%), which can potentially influence treatment decisions. Importantly, our technology permits recovery of the processed tissue for subsequent analysis, including histology examination, immunohistochemistry, and mutation analysis. In conclusion, our novel method has the potential to increase the accuracy of tumor PD-L1 expression assessment and enable precise deployment of cancer immunotherapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03335-5. BioMed Central 2022-03-16 /pmc/articles/PMC8925228/ /pubmed/35296339 http://dx.doi.org/10.1186/s12967-022-03335-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lin, Yen-Yu
Wang, Lei-Chi
Hsieh, Yu-Han
Hung, Yu-Ling
Chen, Yung-An
Lin, Yu-Chieh
Lin, Yen-Yin
Chou, Teh-Ying
Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
title Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
title_full Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
title_fullStr Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
title_full_unstemmed Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
title_short Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
title_sort computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925228/
https://www.ncbi.nlm.nih.gov/pubmed/35296339
http://dx.doi.org/10.1186/s12967-022-03335-5
work_keys_str_mv AT linyenyu computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology
AT wangleichi computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology
AT hsiehyuhan computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology
AT hungyuling computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology
AT chenyungan computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology
AT linyuchieh computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology
AT linyenyin computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology
AT choutehying computerassistedthreedimensionalquantitationofprogrammeddeathligand1innonsmallcelllungcancerusingtissueclearingtechnology